Advertisement
Home »

Risk factor and incidence of serious infections in systemic lupus erythematosus patients undergoing rituximab therapy.

Oct 16, 2023

ABOUT THE CONTRIBUTORS

  • Yi-Syuan Sun

    Yi-Syuan Sun, MD, Division of Allergy, Immunology, and Rheumatology, Department of Medicine, Taipei Veterans General Hospital, Taipei City, Taiwan and and Faculty of Medicine, National Yang Ming Chiao Tung University, Taiwan.

    De-Feng Huang

    De-Feng Huang, MD, Division of Allergy, Immunology, and Rheumatology, Department of Medicine, Taipei Veterans General Hospital, Taipei City, Taiwan.

    Wei-Sheng Chen

    Wei-Sheng Chen, Division of Allergy, Immunology, and Rheumatology, Department of Medicine, Taipei Veterans General Hospital, Taipei City, Taiwan and and Faculty of Medicine, National Yang Ming Chiao Tung University, Taiwan.

    Hsien-Tzung Liao

    Hsien-Tzung Liao, MD, PhD, Division of Allergy, Immunology, and Rheumatology, Department of Medicine, Taipei Veterans General Hospital, Taipei City, Taiwan and and Faculty of Medicine, National Yang Ming Chiao Tung University, Taiwan.

    Ming-Han Chen

    Ming-Han Chen, MD, PhD, Division of Allergy, Immunology, and Rheumatology, Department of Medicine, Taipei Veterans General Hospital, Taipei City, Taiwan and and Faculty of Medicine, National Yang Ming Chiao Tung University, Taiwan.

    Ming-Tsun Tsai

    Ming-Tsun Tsai, MD, PhD, Division of Nephrology, Department of Medicine, Taipei Veterans General Hospital, Taiwan, Institute of Clinical Medicine, School of Medicine, National Yang Ming Chiao Tung University, Taiwan, Faculty of Medicine, School of Medicine, National Yang Ming Chiao Tung University, Taipei Taiwan.

    Chih-Yu Yang

    Chih-Yu Yang, MD, PhD, Division of Nephrology, Department of Medicine, Taipei Veterans General Hospital, Taiwan, Institute of Clinical Medicine, School of Medicine, National Yang Ming Chiao Tung University, Taiwan, Faculty of Medicine, School of Medicine, National Yang Ming Chiao Tung University, Taipei Taiwan, Center for Intelligent Drug Systems and Smart Bio-devices (IDS2B), National Yang Ming Chiao Tung University, Hsinchu, Taiwan, Stem Cell Research Center, National Yang Ming Chiao Tung University, Taipei, Taiwan.

    Chien-Chih Lai

    Chien-Chih Lai, MD, Division of Allergy, Immunology, and Rheumatology, Department of Medicine, Taipei Veterans General Hospital, Taipei City, Taiwan; Faculty of Medicine, National Yang Ming Chiao Tung University, Taiwan and Institute of Clinical Medicine, National Yang Ming Chiao Tung University, Taiwan.

    Chang-Youh Tsai

    Chang-Youh Tsai, MD, PhD, Division of Immunology, and Rheumatology, Department of Medicine, Fu Jen Catholic University Hospital, New Taipei City, Taiwan.

REFERENCES & ADDITIONAL READING

PubMed

MORE ARTICLES BELOW

PW Weekly Newsletters

The latest articles and insights from your colleagues in your specialty(ies) of choice.


Advertisement
Advertisement
ad
ad
MORE ARTICLES BELOW

PW Weekly Newsletters

The latest articles and insights from your colleagues in your specialty(ies) of choice.

SUBSCRIBE NOW

View all newsletters

Advertisement